Leadless Pacemakers
Guidance for a Medicare National Coverage Determination (NCD) which allows for coverage of leadless pacemakers under Coverage with Evidence Development (CED) with certain conditions.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: August 18, 2020
Traditional pacemakers have been the standard treatment option for patients with severe/symptomatic bradycardia, an arrhythmia indicating an unusually slow heart rate. While there have been significant advancements in pacemaker technology since its introduction in 1958, pacemaker devices have continued to require the creation of a surgical pocket under the skin on the upper portion of the chest wall in order to hold the power source, and the use of leads to reach the pacing site. Current leadless pacemaker devices are self-contained enclosed capsules that include the pacemaker electronics and battery, and are delivered via catheter to the right ventricle of the heart. Leadless pacemakers function similarly to traditional single-chamber ventricular pacemakers without requiring transvenous leads or the need for a surgical pocket.
CMS issued a Medicare National Coverage Determination (NCD) on January 18, 2017 which allows for coverage of leadless pacemakers under Coverage with Evidence Development (CED) with certain conditions. The complete determination is available on our website.
Clinical Study Approvals
Study Title: Aveir AR Coverage With Evidence Development (CED) Study (ARRIVE)
Sponsor: Abbott Medical Devices
Clinicaltrials.gov number: NCT06100770
CMS Approval Date: 01/18/2024
Study Title: Aveir DR Coverage With Evidence Development (CED) Study
Sponsor: Abbott Medical Devices
Clinicaltrials.gov number: NCT05932602
CMS Approval Date: 10/31/2023
Study Title: Aveir VR Coverage With Evidence Development Post-Approval Study
Sponsor: Abbott Medical Devices
Clinicaltrials.gov number: NCT05336877
CMS Approval Date: 06/21/2022
Study Title: Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing
Sponsor: Boston Scientific
Clinicaltrials.gov number: NCT04798768
Investigational Device Exemption (IDE) Number: G200319
CMS Approval Date: 01/20/2022
Study Title: The LEADLESS II IDE Study (Phase II): A Safety and Effectiveness Trial for a Leadless Pacemaker System
Sponsor: Abbott Medical Devices
ClinicalTrials.gov Number: NCT04559945
CMS Approval Date: 3/16/2021
Study Title: Longitudinal Coverage With Evidence Development Study on Micra AV Leadless Pacemakers (Micra AV CED)
Sponsor: Medtronic
ClinicalTrials.gov Number: NCT04235491
CMS Approval Date: 2/5/2020
Study Title: The Micra CED Study
Sponsor: Medtronic, Inc
ClinicalTrials.gov Number: NCT03039712
CMS Approval Date: 03/09/2017
Study Title: Micra Transcatheter Pacing System Post-Approval Registry
Sponsor: Medtronic, Inc
ClinicalTrials.gov Number: NCT02536118
PMA Number: P150033
CMS Approval Date: 02/09/2017
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.